Mangsbo SM

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.

Mebrahtu A, Laurén I, Veerman R, ..., Rockberg J, Mangsbo S

Nat Commun 15 (1) 9542 [2024-11-05; online 2024-11-05]

Affinity Proteomics Uppsala [Service] Drug Discovery and Development (DDD) [Service]

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Laurén I, Havervall S, Ng H, ..., Thålin C, Mangsbo S

Immun Inflamm Dis 10 (4) e595 [2022-04-00; online 2022-03-30]

Autoimmunity and Serology Profiling [Collaborative]

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S, Ng H, Jernbom Falk A, ..., Hober S, Thålin C

J. Intern. Med. 291 (1) 72-80 [2022-01-00; online 2021-09-27]

Affinity Proteomics Uppsala [Service] Autoimmunity and Serology Profiling [Collaborative]

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.

Mangsbo SM, Havervall S, Laurén I, ..., Klingström J, Thålin C

PLoS ONE 16 (9) e0258041 [2021-09-30; online 2021-09-30]

Autoimmunity and Serology Profiling [Technology development]

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.

Kerzeli IK, Lord M, Doroszko M, ..., Segersten U, Mangsbo SM

PLoS ONE 16 (7) e0253178 [2021-07-07; online 2021-07-07]

Affinity Proteomics Uppsala [Service] NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]